Replies to post #199 on Belgravia Hartford Cap Inc. (BLGVF)

[PotterBanker]

Belgravia Appoints Dr. Sam Hanna Chief Medical Officer of Cannabis Dermatology Division

TORONTO, April 18, 2018 (GLOBE NEWSWIRE) -- BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (OTCQB:BLGVF) (“Belgravia” or the “Company”) has appointed Dr. Sam Hanna as Chief Medical Officer of its cannabis dermatology division. Dr. Hanna is a well-recognized Canadian dermatologist with experience in numerous clinical studies for dermatology drugs across North America.

https://globenewswire.com/news-release/2018/04/18/1480714/0/en/Belgravia-Appoints-Dr-Sam-Hanna-Chief-Medical-Officer-of-Cannabis-Dermatology-Division.html

[PotterBanker]

Belgravia Completes Transition of ICP Organics to Dermatology Product Development, Renames ICP Organics to Belgravia Dermatology Inc., and Appoints Sidney Himmel Director of Belgravia Dermatology

TORONTO, May 11, 2018 (GLOBE NEWSWIRE) -- BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (OTCQB:BLGVF) (“Belgravia” or the “Company”) today announced that it has completed the strategic transition of ICP Organics, the fully owned subsidiary of Belgravia, to a cannabinoid-based dermatology ethical drug research and product development company. Further, the name of ICP Organics, the dermatology division of Belgravia, is being changed to Belgravia Dermatology Inc. (“Belgravia Dermatology”). The Company has also announced today that Sidney Himmel has been appointed as director of Belgravia Dermatology.

https://globenewswire.com/news-release/2018/05/11/1500957/0/en/Belgravia-Completes-Transition-of-ICP-Organics-to-Dermatology-Product-Development-Renames-ICP-Organics-to-Belgravia-Dermatology-Inc-and-Appoints-Sidney-Himmel-Director-of-Belgravia.html

[PotterBanker]

BELGRAVIA CAPITAL completes acquisition of interest in R&D Pharma Corp., a Canadian corporation building a vertically integrated medical cannabis business in Jamaica

https://globenewswire.com/news-release/2018/05/30/1513731/0/en/BELGRAVIA-CAPITAL-completes-acquisition-of-interest-in-R-D-Pharma-Corp-a-Canadian-corporation-building-a-vertically-integrated-medical-cannabis-business-in-Jamaica.html

TORONTO, May 30, 2018 (GLOBE NEWSWIRE) -- BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (OTCQB:BLGVF) (“Belgravia Capital”, “Belgravia”, or the “Company”) is pleased to announce that it has acquired 10.03% of the outstanding common shares of R&D Pharma Corp. (“RDP”). RDP is a Canadian corporation developing a vertically integrated medicinal cannabis business in Jamaica. Belgravia has acquired four million (4 million) common shares of RDP at a price of twenty-five (25) cents per share. Belgravia has the right to appoint an independent director to the Board of RDP. Mr. Kevin Strong, the Chief Financial Officer (“CFO”) of Belgravia, has been appointed CFO of RDP. The funding of the acquisition was by way of Canadian $500,000 (five-hundred thousand dollars) and 5,000,000 (five million) common shares of Belgravia.